Faslodex Injection
Product Images NDC 0310-0720

16 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Faslodex (NDC 0310-0720). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure14

Figure14
A Kaplan-Meier survival curve showing event-free probability (%) over time in months for two groups: FASLODEX (Fulvestrant) plus Ribociclib (N=484) and FASLODEX plus Placebo (N=242). The chart also notes censoring times and includes a table of patients still at risk at various time points up to 48 months.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
An instructional illustration demonstrating the proper method for withdrawing FASLODEX (Fulvestrant) 50 mg/mL injection from a vial using a syringe. It shows one hand holding the vial and the other drawing fluid with a syringe, alongside a detailed diagram of the syringe and vial components labeled A, B, and C. A crossed-out symbol indicates an incorrect method not to use.*
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
A Kaplan-Meier survival curve showing overall survival probability (%) over time (months) comparing treatment with FASLODEX plus palbociclib versus FASLODEX plus placebo. The graph includes a risk table indicating the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Figure 11

Figure 11
A Kaplan-Meier curve showing progression-free survival probability (%) over time in months for patients treated with FASLODEX plus Abemaciclib versus FASLODEX plus Placebo. The graph includes a legend identifying each treatment group and indicates censored observations with vertical ticks. Below the x-axis, the number of patients at risk at various time points is displayed for both treatment groups.*
FDA Label Image

Figure 12

Figure 12
A Kaplan-Meier survival curve showing survival probability (%) over time (months) comparing FASLODEX plus Abemaciclib versus FASLODEX plus Placebo. The graph includes censored observations and patient counts at risk for both treatment groups at various time points up to 57 months.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
An instructional illustration showing how to use a syringe for injection. The figure includes a hand holding a syringe with the plunger being pulled, and a separate labeled diagram of a vial or container with parts marked A, B, and C, indicating components relevant to drawing medication.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
An instructional illustration showing two hands preparing an injection. One hand holds a syringe with fluid inside, while the other hand manipulates the plunger, indicating the preparation or drawing up of medication for injection.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
An instructional illustration showing the assembly of a syringe with a needle and a vial or ampule, likely related to the preparation or administration of an injection.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
An instructional illustration showing a hand holding a syringe with the thumb pulling back a plunger or cap, indicating a step in preparing the injection. The image is likely part of usage instructions for FASLODEX injection (Fulvestrant) administered intramuscularly.*
FDA Label Image

Figure 6

Figure 6
A Kaplan-Meier survival curve displaying progression-free survival for FASLODEX injection at doses of 250 mg and 500 mg over 45 months. The y-axis shows the proportion of patients progression free, ranging from 0 to 1, while the x-axis represents time in months. The chart includes numbers of patients at risk at various time points for both dosages.*
FDA Label Image

Figure 7

Figure 7
A survival curve chart displaying the proportion of patients alive over time (months) comparing FASLODEX 500 mg and 250 mg doses. The y-axis shows the proportion alive from 0 to 1.0, and the x-axis shows time up to 80 months, with tick marks indicating censored observations. Below the graph, the number of patients at risk for each dose at various time points is provided.*
FDA Label Image

Figure 8

Figure 8
A Kaplan-Meier survival curve chart comparing probability of progression-free survival (PFS) over time (months) between two treatments: FASLODEX 500 mg and Anastrozole 1 mg. The x-axis represents time from randomization in months, and the y-axis shows probability of PFS. The chart includes patient numbers at risk over time for both treatments in a table below the graph.*
FDA Label Image

Figure 9

Figure 9
A Kaplan-Meier curve chart displaying progression-free survival probability (%) over time in months for patients treated with FASLODEX plus palbociclib versus FASLODEX plus placebo. The plot shows two survival curves, with a table of patient numbers at risk below the x-axis, indicating comparative outcomes for each treatment group over 14 months.*
FDA Label Image

Ndc0310 0720 10

Ndc0310 0720 10
Packaging label for FASLODEX fulvestrant injection, 250 mg/5 mL (50 mg/mL) for intramuscular use only. The carton contains 2 single-dose prefilled syringes, providing a total of 500 mg fulvestrant. Labeler is AstraZeneca Pharmaceuticals LP. Storage instructions include refrigeration and protection from light.*
FDA Label Image

Chemical Structure Faslodex (Chemical Structure Faslodex)

Chemical Structure Faslodex (Chemical Structure Faslodex)
Chemical structure of Fulvestrant, the active ingredient in FASLODEX 50 mg/mL injection by AstraZeneca Pharmaceuticals LP. The diagram shows the molecular framework including hydroxyl groups and a long alkyl sulfonyl trifluoromethyl side chain.*
FDA Label Image

Figure12

Figure12
A Kaplan-Meier survival curve chart showing event-free probability (%) over time in months for two groups: FASLODEX plus Ribociclib (484 patients) and FASLODEX plus Placebo (242 patients). The chart includes censoring times indicated by symbols, with a table below listing the number of patients still at risk at various time points up to 26 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.